Home > Oncology > U.S. FDA approves Novartis therapy for prostate cancer

U.S. FDA approves Novartis therapy for prostate cancer


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Reuters - 23/03/2022 - The U.S. Food and Drug Administration approved Novartis AG's therapy for the treatment of patients with a type of advanced prostate cancer that has spread to other parts of the body, the drugmaker said on Wednesday. Novartis' Pluvicto is a targeted radioligand therapy for adult patients who have already undergone other anticancer treatments. The company bought the therapy as part of its $2.1 billion purchase of cancer drugmaker Endocyte in 2018. Pluvicto is a precision treatment combining a targeting compound, or ligand, with a cancer-killing radioactive particle, Novartis said. The company said it has submitted marketing authorization for Pluvicto to the European Medicines Agency and other health authorities. Two late-stage studies evaluating Pluvicto in earlier lines of treatment for metastatic prostate cancer are underway, according to Novartis.


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on